メインコンテンツにスキップ

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

PRINCETON, NJ – 2024年4月16日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions. Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to … Continued

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

PRINCETON, N.J.— 2024年4月9日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening … Continued

Certara Reports Fourth Quarter 2023 Financial Results

Provides Full Year 2024 Financial Guidance PRINCETON, N.J.— 2024年2月29日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023. Fourth Quarter Highlights: “We are encouraged by our strong fourth quarter results, driven by improved execution across both software and services,” said William … Continued

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at … Continued

サターラ、Applied Biomath社を買収:バイオシミュレーションポートフォリオを拡大し、新規治療薬の最適投与に向けた新機能を強化

両社の統合によりライフサイエンス業界最大の定量的システム薬理学(QSP)支援体制が確立され、より迅速で効果的な医薬品開発に貢献します。2023年12月14日、ニュージャージー州プリンストン - バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT) today announced it has acquired Applied Biomath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and … Continued

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies Princeton, NJ – November 21st, 2023 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating complex … Continued

サターラ が2023年第3四半期決算を報告

 Reiterates Full Year 2023 Financial Guidance PRINCETON, N.J.— November 8, 2023– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023. Third Quarter Highlights: “During the third quarter we saw customer demand stabilize across the Certara platform. We continue to see strong interest from … Continued

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday November 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors … Continued

Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software

Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines. PRINCETON, NJ – September 19th,  2023 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to regulatory agencies worldwide. Submissions include those to initiate clinical trials, such as Investigational New Drug (IND) or Clinical … Continued

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 29, 2023 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Live webcasts for each of the conferences will be available on Certara’s investor relations website athttps://ir.certara.com and will be available for replay for at least 90 days thereafter. … Continued

1 of 33
Powered by Translations.com GlobalLink OneLink Software